Lyell Immunopharma IncLYEL
Price$9.41

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $27K-55.7% YoYTTM through 30 Jun 2026
Net Income -$248.5MTTM through 30 Jun 2026
Free Cash Flow -$134MTTM through 30 Jun 2026

Margins

Current
Operating Margin-60,151,613.0%
Net Margin-920,285.2%

Returns

-106.3%ROE
-79.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.36x
Net Debt-$261Mnet cash position
Cash & Equivalents$73M

Quality Metrics

Altman Z-Score-7.53
Piotroski F-Score2 / 9
FCF Margin-496,188.9%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $36K
Diluted EPS-$12.69TTM
'19'20'21'22'23'24'25
FY2025: $-16.06

Dividend

No dividend

Capital Allocation

Capex Intensity2,633.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.